Improved ocular: systemic absorption ratio of timolol by viscous vehicle and phenylephrine.
Increasing the ocular absorption of timolol relative to its systemic absorption is important clinically because ophthalmic timolol may cause serious respiratory, cardiac, and central nervous system side effects. The authors evaluated the effects of phenylephrine coadministration and solution viscosity on the aqueous humor:plasma and iris ciliary body:plasma ratios of peak timolol concentrations after ocular application. Timolol eye drops (5 mg/ml, 25 microliters) were administered to the eyes of pigmented rabbits. Coadministered phenylephrine (0.8-8.2 mg/ml) decreased the systemic peak concentrations of timolol significantly. Since ocular absorption of timolol was not affected by phenylephrine, the ocular:systemic concentration ratios were improved four- to fivefold. Phenylephrine slows down the systemic absorption of timolol by constricting the conjunctival and nasal capillaries. The ratios of the aqueous humor:plasma and iris ciliary body:plasma peak concentration of timolol were improved three- to ninefold in the presence of sodium carboxymethylcellulose compared with nonviscous eye drops. The improved ocular penetration is probably due to the longer corneal contact, and the decreased rate of systemic absorption may be caused by the slower spreading of the solution on the nasal mucosa. Compared with timolol eye drops, the ratio of the eye:plasma peak timolol concentrations was improved tenfold by using viscous eye drops with phenylephrine. Systemic concentrations of ophthalmic timolol and possibly related side effects can be decreased when timolol is instilled in a viscous vehicle with a low phenylephrine concentration.
Kyyrönen
K
K
Department of Pharmaceutical Technology, University of Kuopio, Finland.
Urtti
A
A
D000042:Absorption; D000287:Administration, Topical; D000818:Animals; D000869:Anterior Eye Segment / Q000378:metabolism*; D001082:Aqueous Humor / Q000378:metabolism; D002266:Carboxymethylcellulose Sodium / Q000008:administration & dosage* / Q000494:pharmacology; D003228:Conjunctiva / Q000378:metabolism; D003315:Cornea / Q000378:metabolism; D005260:Female; D007498:Iris / Q000378:metabolism; D008297:Male; D014677:Pharmaceutical Vehicles; D010656:Phenylephrine / Q000008:administration & dosage* / Q000494:pharmacology; D011817:Rabbits; D012590:Sclera / Q000378:metabolism; D013999:Timolol / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D014018:Tissue Distribution; D014661:Vasoconstriction; D014783:Viscosity
D014677:Pharmaceutical Vehicles; D010656:Phenylephrine; D013999:Timolol; D002266:Carboxymethylcellulose Sodium